ATE525484T1 - Slco1b3-genotyp - Google Patents
Slco1b3-genotypInfo
- Publication number
- ATE525484T1 ATE525484T1 AT08713083T AT08713083T ATE525484T1 AT E525484 T1 ATE525484 T1 AT E525484T1 AT 08713083 T AT08713083 T AT 08713083T AT 08713083 T AT08713083 T AT 08713083T AT E525484 T1 ATE525484 T1 AT E525484T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- determining
- prostate cancer
- differences
- slco1b3
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87950307P | 2007-01-08 | 2007-01-08 | |
| PCT/US2008/000310 WO2008086002A2 (en) | 2007-01-08 | 2008-01-08 | Slco1b3 genotype |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525484T1 true ATE525484T1 (de) | 2011-10-15 |
Family
ID=39609290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08713083T ATE525484T1 (de) | 2007-01-08 | 2008-01-08 | Slco1b3-genotyp |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10094836B2 (de) |
| EP (1) | EP2115173B1 (de) |
| AT (1) | ATE525484T1 (de) |
| AU (1) | AU2008205330B2 (de) |
| CA (1) | CA2674788A1 (de) |
| WO (1) | WO2008086002A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ572036A (en) | 2008-10-15 | 2010-03-26 | Nikola Kirilov Kasabov | Data analysis and predictive systems and related methodologies |
| US10273544B2 (en) | 2010-02-11 | 2019-04-30 | Dana-Farber Cancer Institute, Inc. | Methods for predicting likelihood of responding to treatment |
| EP2614158A4 (de) * | 2010-09-08 | 2014-03-19 | Mayo Foundation | Vorhersage von reaktionen auf eine androgendeprivationstherapie |
| CN102952872B (zh) * | 2011-08-29 | 2014-06-18 | 益善生物技术股份有限公司 | 一种slco1b3基因多态性检测特异性引物和液相芯片 |
| JP6203394B2 (ja) | 2013-07-15 | 2017-09-27 | ザ クリーブランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ ＣｌｉｎｉｃＦｏｕｎｄａｔｉｏｎ | ステロイド依存性疾患における３β−ヒドロキシステロイドデヒドロゲナーゼ |
| US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| JP6765433B2 (ja) | 2016-02-12 | 2020-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 異常な核型の検出のための方法 |
| WO2018038943A1 (en) * | 2016-08-11 | 2018-03-01 | Siemens Healthcare Diagnostics Inc. | Heating device for a filtration assembly |
| CN112415206B (zh) * | 2020-10-23 | 2023-08-18 | 上海良润生物医药科技有限公司 | 外泌体中的cd171蛋白作为肿瘤转移诊断标志物的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
| US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5652138A (en) | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| US7258973B2 (en) * | 1998-08-31 | 2007-08-21 | Mayo Foundation For Medical Education & Research | Method for detecting a differentially expressed sequence |
| US7169187B2 (en) | 1999-12-22 | 2007-01-30 | Ethicon, Inc. | Biodegradable stent |
| WO2001049338A1 (en) | 1999-12-30 | 2001-07-12 | Li Wei Pin | Controlled delivery of therapeutic agents by insertable medical devices |
| JP2003144176A (ja) * | 2000-12-27 | 2003-05-20 | Inst Of Physical & Chemical Res | 遺伝子多型の検出方法 |
| EP1446044A4 (de) * | 2001-02-09 | 2007-08-08 | Pintex Pharmaceuticals Inc | Pin1 als marker für prostatakrebs |
| AU784552B2 (en) | 2001-03-02 | 2006-05-04 | Cardinal Health 529, Llc | Flexible stent |
| AU2002307466A1 (en) * | 2001-04-20 | 2002-11-05 | Millennium Pharmaceutical, Inc. | Method for detecting breast cancer cells |
| AUPR969201A0 (en) | 2001-12-20 | 2002-01-24 | White, Geoffrey H. | A device for use in intraluminal grafting |
| GB0213579D0 (en) * | 2002-06-13 | 2002-07-24 | Astrazeneca Ab | Methods |
| US20050163821A1 (en) | 2002-08-02 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting Biodegradable Stent and Delivery Means |
| US7153658B2 (en) | 2002-09-19 | 2006-12-26 | Applera Corporation | Methods and compositions for detecting targets |
| US20050149166A1 (en) | 2003-11-08 | 2005-07-07 | Schaeffer Darin G. | Branch vessel prosthesis with anchoring device and method |
| US7468070B2 (en) | 2004-01-23 | 2008-12-23 | Boston Scientific Scimed, Inc. | Stent delivery catheter |
| US7803178B2 (en) | 2004-01-30 | 2010-09-28 | Trivascular, Inc. | Inflatable porous implants and methods for drug delivery |
-
2008
- 2008-01-08 CA CA002674788A patent/CA2674788A1/en not_active Abandoned
- 2008-01-08 AU AU2008205330A patent/AU2008205330B2/en not_active Ceased
- 2008-01-08 EP EP08713083A patent/EP2115173B1/de not_active Not-in-force
- 2008-01-08 WO PCT/US2008/000310 patent/WO2008086002A2/en not_active Ceased
- 2008-01-08 AT AT08713083T patent/ATE525484T1/de not_active IP Right Cessation
- 2008-01-08 US US12/522,480 patent/US10094836B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100317726A1 (en) | 2010-12-16 |
| WO2008086002A2 (en) | 2008-07-17 |
| CA2674788A1 (en) | 2008-07-17 |
| AU2008205330B2 (en) | 2014-07-03 |
| WO2008086002A3 (en) | 2008-10-23 |
| AU2008205330A1 (en) | 2008-07-17 |
| EP2115173B1 (de) | 2011-09-21 |
| US10094836B2 (en) | 2018-10-09 |
| EP2115173A2 (de) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7160023A2 (es) | Métodos y aparatos para predecir riesgo de cáncer de próstata y volumen de glándula prostática | |
| WO2008086002A3 (en) | Slco1b3 genotype | |
| GB201021289D0 (en) | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer | |
| IL233098A (en) | Methods for detecting cancer and determining prognosis and survival probabilities and ratio based biomarkers for use therein | |
| AR066725A1 (es) | Prediccion del pronostico para melanoma de cancer | |
| IN2013CN01129A (de) | ||
| WO2008097908A3 (en) | Methods of diagnosing and prognosing lung cancer | |
| GB0720113D0 (en) | Diagnostic, prognostic and predictive testing for cancer | |
| NZ606725A (en) | Methods for predicting anti-cancer response | |
| MX2013003077A (es) | Diagnostico de cancer de mama. | |
| ZA200803517B (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| IL190852A0 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| WO2008104543A3 (en) | Method for predicting the occurrence of metastasis in breast cancer patients | |
| ZA200804509B (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| WO2010004589A3 (en) | Genetic variants predictive of cancer risk in humans | |
| WO2010009337A3 (en) | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof | |
| WO2012166899A3 (en) | Biomarkers for predicting and assessing responsiveness to lenvatinib compounds | |
| ZA200803516B (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| BR112012026536A2 (pt) | sistemas e métodos para predizer deficiência gastrointestinal | |
| BRPI0716391A2 (pt) | método de previsão de metástase distante de câncer de mama primário nódulo linfático-negativo usando análise de expressão gênica de via biloógica | |
| IL205347A0 (en) | Process for predicting the prognosis of squamous cell lung cancer | |
| EP1934603A4 (de) | Biomarker für prostatakrebs | |
| MX2009008247A (es) | Biomarcadores de respuesta a la radiacion ionizante. | |
| GB0512299D0 (en) | Diagnosis prognosis and prediction of recurrence of breast cancer | |
| PL2024748T3 (pl) | Przeciwciała monoklonalne przeciw aneksynie A3 do wykrywania raka gruczołu krokowego |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |